Analysis of the changes induced by bevacizumab using a high temporal resolution DCE-MRI as prognostic factors for response to further neoadjuvant chemotherapy

Background Antiangiogenic drugs are being used in the treatment of locally advanced breast cancer. The effect of these drugs can be monitorized using high temporal resolution dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Purpose To evaluate changes in tumor microvasculature induced...

Full description

Saved in:
Bibliographic Details
Published in:Acta radiologica (1987) 2015-11, Vol.56 (11), p.1300-1307
Main Authors: Etxano, Jon, Insausti, Luis Pina, Elizalde, Arlette, López Vega, José Manuel, Plazaola, Arrate, Martínez, Purificación
Format: Article
Language:English
Subjects:
Adult
Aged
Angiogenesis Inhibitors - pharmacokinetics
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab - pharmacokinetics
Bevacizumab - therapeutic use
Breast
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Cancer
Chemotherapy
Chemotherapy, Adjuvant
Drugs
Female
Humans
Image Interpretation, Computer-Assisted
Magnetic Resonance Imaging - methods
Middle Aged
Monitoring
Neoadjuvant Therapy
Neoplasm Staging
Organometallic Compounds
Prognosis
Prospective Studies
Temporal resolution
Therapy
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Antiangiogenic drugs are being used in the treatment of locally advanced breast cancer. The effect of these drugs can be monitorized using high temporal resolution dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Purpose To evaluate changes in tumor microvasculature induced by bevacizumab and the usefulness of these changes predicting response to further neoadjuvant therapy. Material and Methods Seventy patients with locally advanced breast cancers were treated with one cycle of bevacizumab followed by neoadjuvant therapy, combining bevacizumab and cytotoxic chemotherapy. Two DCE-MRI were performed before and after bevacizumab. Changes in tumoral volume, pharmacodynamic curves, and pharmacokinetic variables (Ktrans, Kep, Ve, AUC90) in a ROI (ROI 1) encompassing the entire tumor and in another ROI (ROI 2) in the area of higher values of Ktrans were analyzed. Correlations with pathological response were made: parametrical and non-parametrical statistical analysis and ROC curves were used; a P 
ISSN:0284-1851
1600-0455
DOI:10.1177/0284185114556098